


## CLAIMS

1. A method for treating rheumatoid arthritis by PDT,  
comprising administering an iminochlorine aspartic acid derivative of  
5 the following formula (I):



wherein Asp represents aspartic acid residue;  
or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the  
10 iminochlorine aspartic acid derivative of the formula (I) or a  
pharmaceutically acceptable salt thereof is a sodium salt.

3. A therapeutic agent for use in PDT of rheumatoid  
arthritis, comprising as an active ingredient the iminochlorine  
aspartic acid derivative of the formula (I) of claim 1 or a  
15 pharmaceutically acceptable salt thereof.

4. The therapeutic agent according to claim 3, wherein the  
iminochlorine aspartic acid derivative of the formula (I) or a  
pharmaceutically acceptable salt thereof is a sodium salt.

5. Use of the iminochlorine aspartic acid derivative of the  
20 formula (I) of claim 1 or a pharmaceutically acceptable salt thereof  
in PDT of rheumatoid arthritis.

6. The use according to claim 5, wherein the iminochlorine  
aspartic acid derivative of the formula (I) or a pharmaceutically  
acceptable salt thereof is a sodium salt.

7. A method for treating inflammatory keratosis by PDT, comprising administering the iminochlorine aspartic acid derivative of the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof.

5 8. The method according to claim 7, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt.

9. A therapeutic agent for use in PDT of inflammatory keratosis, comprising as an active ingredient the iminochlorine  
10 aspartic acid derivative of the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof.

10. The therapeutic agent according to claim 9, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt.

15 11. Use of the iminochlorine aspartic acid derivative of the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof in PDT of inflammatory keratosis.

12. The use according to claim 11, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically  
20 acceptable salt thereof is a sodium salt.

13. A method for determining the location of a sentinel lymph node and the presence of cancer metastasis by PDT, comprising administering the iminochlorine aspartic acid derivative of the formula (I) of claim 1 and a pharmaceutically acceptable salt thereof.

25 14. The method according to claim 13, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt.

15. A diagnostic agent for determining the location of a sentinel lymph node and the presence of cancer metastasis by PDT,  
30 comprising as an active ingredient the iminochlorine aspartic acid derivative of the formula (I) of claim 1 and a pharmaceutically

acceptable salt thereof.

16. The diagnostic agent according to claim 15, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt.

5 17. Use of the iminochlorine aspartic acid derivative of the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof in PDT to determine the location of a sentinel lymph node and the presence of cancer metastasis.

10 18. The use according to claim 17, wherein the iminochlorine aspartic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt.